Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Kiniksa Pharmaceuticals, Ltd. (KNSA) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/28/2023 8-K Quarterly results
Docs: "Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution"
08/03/2022 8-K Quarterly results
Docs: "Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update",
"Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab"
05/03/2022 8-K Quarterly results
Docs: "Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update"
02/22/2022 8-K Quarterly results
Docs: "KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue: Product revenue, net $ 18,745 $ — $ 38,544 $ — Operating expenses: Cost of goods sold 3,867 — 9,100 — Collaboration expenses 835 — 835 — Research and development 27,433 37,398 99,297 112,042 Selling, general and administrative 22,741 15,500 85,948 45,321 Total operating expenses 54,876 52,898 195,180 157,363 Loss from operations Interest income 77 30 97 1,134 Loss before provision for income taxes Provision for income taxes Net loss $ $ $ $ Net loss per share attributable to common shareholders —basic and diluted $ $ $ $ Weighted average common shares outstanding—basic and diluted 68,970,730 68,062,007 68,576,810 61,842,722 KINIKSA...",
"Huadong Medicine Investor and Media Contact"
11/01/2021 8-K Quarterly results
Docs: "Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution"
08/03/2021 8-K Quarterly results
Docs: "KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Revenue: Product revenue, net $ 7,704 $ — $ 7,704 $ — Costs and operating expenses: Cost of goods sold 2,466 — 2,466 — Research and development 23,945 22,324 52,628 43,225 Selling, general and administrative 21,848 9,536 42,448 18,022 Total operating expenses 48,259 31,860 97,542 61,247 Loss from operations Interest income 6 266 15 1,055 Loss before provision for income taxes Provision for income taxes Net loss $ $ $ $ Net loss per share attributable to common shareholders—basic and diluted $ $ $ $ Weighted average common shares outstanding—basic and diluted 68,395,703 57,914,105 68,332,943 56,618,397 KINIKSA PHARMACEUTICALS, LTD. SELECTED CON..."
05/04/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity"
07/30/2020 8-K Quarterly results
04/28/2020 8-K Quarterly results
Docs: "Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity"
02/26/2020 8-K Quarterly results
Docs: "Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity"
10/28/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
05/02/2019 8-K Quarterly results
Docs: "Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity"
11/01/2018 8-K Quarterly results
Docs: "Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress"
08/06/2018 8-K Quarterly results
Docs: "Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy